Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of sofosbuvir + daclatasvir in outpatients with COVID-19
IRCT20200128046294N3Phase 2Completed
- Sponsor
- Tehran University of Medical Sciences
- Start
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sofosbuvir and daclatasvir in coronavirus disease 2019 (COVID-19), sponsored by Tehran University of Medical Sciences. Primary endpoint: Any related or non related adverse events occurred during study period. Started Oct 2020; status: completed.
02
Drugs
sofosbuvirdaclatasvir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on IRCT20200128046294N3.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20200128046294N3.